Zanamivir - Latest Advances

Exploring Drug Repurposing for Influenza A (H3N2) Virus: A Computational Approach to Identifying Commercialized Drugs Targeting Hemagglutinin, Neuraminidase, and Nucleoprotein.

Journal: Journal of chemical information and modeling

Published: October 18, 2025

Zanamivir exposure in healthy rats and rats with acute lung injury.

Journal: Annals of medicine

Published: July 20, 2025

One-shot flu drug may beat vaccines.

Journal: Science (New York, N.Y.)

Published: July 03, 2025

Swine influenza virus surveillance programme pilot to assess the risk for animal and public health, the Netherlands, 2022 to 2023.

Journal: Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin

Published: June 06, 2025

Repurposing of Some Nucleoside Analogs Targeting Some Key Proteins of the Avian H5N1 Clade 2.3.4.4b to Combat the Circulating HPAI in Birds: An In Silico Approach.

Journal: Viruses

Published: June 01, 2025

Oral nanoformulation of a host-directed antiviral niclosamide effectively treats severe fever with thrombocytopenia syndrome.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: May 28, 2025

Report on influenza viruses received and tested by the Melbourne WHO Collaborating Centre for Reference and Research on Influenza during 2023.

Journal: Communicable diseases intelligence (2018)

Published: May 18, 2025

Small Molecule Influenza Virus Fusion Inhibitors Targeting Viral Hemagglutinin: Chemical Insights and Antiviral Evaluation.

Journal: Mini reviews in medicinal chemistry

Published: April 30, 2025

Discovery of Novel Natural Inhibitors of H5N1 Neuraminidase Using Integrated Molecular Modeling and ADMET Prediction.

Journal: Bioengineering (Basel, Switzerland)

Published: April 30, 2025

Epidemiological and genomic surveillance of influenza A virus (pdm09 H1N1 and H3N2) strains from 2017 to 2025 in Tianjin, China.

Journal: Virologica Sinica

Published: April 21, 2025

Prophylactic Efficacy of CD388, a Novel Drug-Fc Conjugate, in a Human Influenza A/H3N2 Virus Challenge Model: A Randomized, Controlled Phase 2a Study.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: April 11, 2025

Updated insights on memory disorder associated risk of medication: A real-world pharmacovigilance analysis.

Journal: Journal of affective disorders

Published: April 08, 2025

Filters

Exploring Drug Repurposing for Influenza A (H3N2) Virus: A Computational Approach to Identifying Commercialized Drugs Targeting Hemagglutinin, Neuraminidase, and Nucleoprotein.

Exploring Drug Repurposing for Influenza A (H3N2) Virus: A Computational Approach to Identifying Commercialized Drugs Targeting Hemagglutinin, Neuraminidase, and Nucleoprotein.

Zanamivir exposure in healthy rats and rats with acute lung injury.

Zanamivir exposure in healthy rats and rats with acute lung injury.

One-shot flu drug may beat vaccines.

One-shot flu drug may beat vaccines.

Swine influenza virus surveillance programme pilot to assess the risk for animal and public health, the Netherlands, 2022 to 2023.

Swine influenza virus surveillance programme pilot to assess the risk for animal and public health, the Netherlands, 2022 to 2023.

Repurposing of Some Nucleoside Analogs Targeting Some Key Proteins of the Avian H5N1 Clade 2.3.4.4b to Combat the Circulating HPAI in Birds: An In Silico Approach.

Repurposing of Some Nucleoside Analogs Targeting Some Key Proteins of the Avian H5N1 Clade 2.3.4.4b to Combat the Circulating HPAI in Birds: An In Silico Approach.

Oral nanoformulation of a host-directed antiviral niclosamide effectively treats severe fever with thrombocytopenia syndrome.

Oral nanoformulation of a host-directed antiviral niclosamide effectively treats severe fever with thrombocytopenia syndrome.

Report on influenza viruses received and tested by the Melbourne WHO Collaborating Centre for Reference and Research on Influenza during 2023.

Report on influenza viruses received and tested by the Melbourne WHO Collaborating Centre for Reference and Research on Influenza during 2023.

Small Molecule Influenza Virus Fusion Inhibitors Targeting Viral Hemagglutinin: Chemical Insights and Antiviral Evaluation.

Small Molecule Influenza Virus Fusion Inhibitors Targeting Viral Hemagglutinin: Chemical Insights and Antiviral Evaluation.

Discovery of Novel Natural Inhibitors of H5N1 Neuraminidase Using Integrated Molecular Modeling and ADMET Prediction.

Discovery of Novel Natural Inhibitors of H5N1 Neuraminidase Using Integrated Molecular Modeling and ADMET Prediction.

Epidemiological and genomic surveillance of influenza A virus (pdm09 H1N1 and H3N2) strains from 2017 to 2025 in Tianjin, China.

Epidemiological and genomic surveillance of influenza A virus (pdm09 H1N1 and H3N2) strains from 2017 to 2025 in Tianjin, China.

Prophylactic Efficacy of CD388, a Novel Drug-Fc Conjugate, in a Human Influenza A/H3N2 Virus Challenge Model: A Randomized, Controlled Phase 2a Study.

Prophylactic Efficacy of CD388, a Novel Drug-Fc Conjugate, in a Human Influenza A/H3N2 Virus Challenge Model: A Randomized, Controlled Phase 2a Study.

Updated insights on memory disorder associated risk of medication: A real-world pharmacovigilance analysis.

Updated insights on memory disorder associated risk of medication: A real-world pharmacovigilance analysis.